Skip to main content
Premium Trial:

Request an Annual Quote

The Downside: Then You Have to Label the Patients "GMO"

This article in the Guardian describes a DNA-based vaccine for multiple sclerosis that's gone through in human trials and "has been declared a success by doctors in America after tests on patients revealed signs that their condition had improved," according to the story. The vaccine contains DNA responsible for producing myelin, which serves to prevent the immune system from going haywire and causing MS.

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.